GRATACOS-MASMITJA, J., A. TURKIEWICZ, Eva DOKOUPILOVÁ, A. M. GELLETT, T. SPRABERY, V. J, GENEUS a A. CONSTANTIN. EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2). Online. 2020. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2020-eular.1482. [citováno 2024-04-24] |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1746218, author = {GratacosandMasmitja, J. and Turkiewicz, A. and Dokoupilová, Eva and Gellett, A. M. and Sprabery, T. and Geneus, V. J, and Constantin, A.}, doi = {http://dx.doi.org/10.1136/annrheumdis-2020-eular.1482}, keywords = {efficacy; safety; ixekizumab; patients; psoriatic arthritis; inadequate response; inhibitors}, language = {eng}, title = {EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)}, url = {https://ard.bmj.com/content/79/Suppl_1/1158.1}, year = {2020} }
TY - CONF ID - 1746218 AU - Gratacos-Masmitja, J. - Turkiewicz, A. - Dokoupilová, Eva - Gellett, A. M. - Sprabery, T. - Geneus, V. J, - Constantin, A. PY - 2020 TI - EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2) KW - efficacy KW - safety KW - ixekizumab KW - patients KW - psoriatic arthritis KW - inadequate response KW - inhibitors UR - https://ard.bmj.com/content/79/Suppl_1/1158.1 N2 - Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In the SPIRIT-P2 study, IXE every 4 (Q4W) or 2 (Q2W) weeks was superior to placebo (PBO) in improving the signs and symptoms of psoriatic arthritis (PsA) at Week 24 in patients (pts) with prior inadequate response or intolerance to 1 or 2 tumor necrosis factor inhibitors (TNFi). ER -
GRATACOS-MASMITJA, J., A. TURKIEWICZ, Eva DOKOUPILOVÁ, A. M. GELLETT, T. SPRABERY, V. J, GENEUS a A. CONSTANTIN. \textit{EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)}. Online. 2020. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2020-eular.1482. [citováno 2024-04-24]
|